 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| Company |
Scientific Advisory Board (SAB)
PNB's CEO / CSO Dr. Erik Buntinx was able to install an unrivaled
world class SAB with Dr. Charles Nemeroff, Emory, Dr. Alan F.
Shatzberg, Stanford and Dr. Th. Schlaepfer, Bonn.
The SAB is closely involved in
1. ongoing validation of the scientific concept,
2. development of clinical trial plans and
3. assessing the potential for a multi-drug line opportunity
Charles Nemeroff, MD, PhD, the Reunette W. Harris Professor
and Chairman of the Department of Psychiatry and Behavioral
Sciences at the Emory University School of Medicine in Atlanta,
Georgia, USA.
Alan F. Shatzberg, MD, the Kenneth T. Norris Jr. Professor and
Chair of the Department of Psychiatry and Behavioral Sciences
at Stanford University, USA.
Thomas Schlaepfer, MD, Professor and Vice Chair of the
Department of Psychiatry and Psychotherapy at the University
of Bonn in Germany.
PNB's CEO / CSO Dr. Erik Buntinx was able to install an unrivaled
world class SAB with Dr. Charles Nemeroff, Emory, Dr. Alan F.
Shatzberg, Stanford and Dr. Th. Schlaepfer, Bonn.
The SAB is closely involved in
1. ongoing validation of the scientific concept,
2. development of clinical trial plans and
3. assessing the potential for a multi-drug line opportunity
Charles Nemeroff, MD, PhD, the Reunette W. Harris Professor
and Chairman of the Department of Psychiatry and Behavioral
Sciences at the Emory University School of Medicine in Atlanta,
Georgia, USA.
Alan F. Shatzberg, MD, the Kenneth T. Norris Jr. Professor and
Chair of the Department of Psychiatry and Behavioral Sciences
at Stanford University, USA.
Thomas Schlaepfer, MD, Professor and Vice Chair of the
Department of Psychiatry and Psychotherapy at the University
of Bonn in Germany.
| © PharmaNeuroBoost 2012 - All Rights Reserved |
|  |  |  |  |  |  |  |  |
Publications
| News Highlights |
April 2nd, 2012
PharmaNeuroBoost
invited to present the
novel pharmacological
concept of its clinical
stage antipsychotic
PNB02 at the high
level CNS meeting
NCDEU in Phoenix,
USA, on May 29th
2012.
September 30th, 2011
First Patients Enrolled
in the PNB01 Phase III
clinical develop- ment
program in Major
Depression
PharmaNeuroBoost
invited to present the
novel pharmacological
concept of its clinical
stage antipsychotic
PNB02 at the high
level CNS meeting
NCDEU in Phoenix,
USA, on May 29th
2012.
September 30th, 2011
First Patients Enrolled
in the PNB01 Phase III
clinical develop- ment
program in Major
Depression